Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692005 | 0.85 | MMEL1 (0.54) | MMEL1L3MBTL1ATMCTRB1MEN1 | |
| SCHEMBL18065507 | 0.85 | MMEL1 (0.54) | MMEL1L3MBTL1ATMCTRB1MEN1 | |
| SCHEMBL6599770 | 0.74 | GAA (0.47) | GAAMEN1KMT2A | |
| SCHEMBL5916354 | 0.73 | KLK5 (0.60) | ATMKMT2AACE | |
| SCHEMBL8647459 | 0.72 | KLK5 (0.61) | MMEL1ATMKMT2AACE | |
| SCHEMBL8647455 | 0.72 | KLK5 (0.61) | MMEL1ATMKMT2AACE | |
| SCHEMBL7269454 | 0.72 | KLK5 (0.61) | MMEL1ATMKMT2AACE | |
| SCHEMBL7267752 | 0.71 | ACE (0.60) | ATMKMT2AACE | |
| SCHEMBL7393230 | 0.71 | ACE (0.60) | ATMKMT2AACE | |
| SCHEMBL19645374 | 0.70 | CTRB1 (0.48) | CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066065-B1 | CATALYTIC HYDROGENATION FOR THE PREPARATION OF AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID AMIDES, DI-, TRI- OR POLYPEPTIDES OR PEPTIDE AMIDES | EVONIK DEGUSSA GMBH (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-2868643-A1 | Catalytic hydrogenation for the preparation of amines from carboxylic acid amides, carboxylic acid amides, di-, tri- or polypeptides or peptide amides | Evonik Industries AG (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | MMEL1 560/4885L3MBTL1 3877/4885ATM 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.